Treatment Guidelines for Vaginal Herpes Simplex

First Clinical Episode Treatment

• The Centers for Disease Control and Prevention recommends antiviral regimens for first episodes, including Acyclovir 400 mg orally three times daily for 7-10 days, Acyclovir 200 mg orally five times daily for 7-10 days, Famciclovir 250 mg orally three times daily for 7-10 days, and Valacyclovir 1 g orally twice daily for 7-10 days 1, 2
• Treatment may be extended if healing is incomplete after 10 days of therapy, as recommended by the Centers for Disease Control and Prevention 1
• Higher dosages of acyclovir may be required for severe cases, particularly in immunocompromised patients, according to the Centers for Disease Control and Prevention 2

Recurrent Episodes Treatment

• The American College of Obstetricians and Gynecologists recommends episodic therapy options for recurrent episodes, including Valacyclovir 500 mg orally twice daily for 5 days, Acyclovir 400 mg orally three times daily for 5 days, Acyclovir 800 mg orally twice daily for 5 days, Acyclovir 200 mg orally five times daily for 5 days, and Famciclovir 125 mg orally twice daily for 5 days 3
• Episodic therapy is most effective when started during the prodrome or within 1 day after onset of lesions, as stated by the Centers for Disease Control and Prevention 4
• Patients should be provided with medication or a prescription to initiate treatment at the first sign of prodrome or genital lesions, according to the Centers for Disease Control and Prevention 4

Suppressive Therapy

• The Centers for Disease Control and Prevention recommends daily suppressive therapy for patients with frequent recurrences (≥6 episodes per year) 4, 3
• Suppressive therapy options include Valacyclovir 1 g orally once daily, Valacyclovir 500 mg orally once daily, Acyclovir 400 mg orally twice daily, and Famciclovir 250 mg orally twice daily, as recommended by the American College of Obstetricians and Gynecologists 3, 5
• Suppressive therapy reduces recurrence frequency by ≥75%, according to the Centers for Disease Control and Prevention 4
• Safety and efficacy have been documented for acyclovir for up to 6 years and for valacyclovir and famciclovir for 1 year, as stated by the Centers for Disease Control and Prevention 4
• After 1 year of continuous suppressive therapy, consider discontinuation to assess recurrence frequency, as recommended by the Centers for Disease Control and Prevention 4

Important Clinical Considerations

• Topical acyclovir is substantially less effective than oral therapy and is not recommended, according to the Centers for Disease Control and Prevention 2

Patient Education and Counseling

• Patients should be counseled about the natural history of genital herpes, including potential for recurrent episodes, asymptomatic viral shedding, and sexual transmission, as recommended by the Centers for Disease Control and Prevention 1
• Patients should be counseled to abstain from sexual activity when lesions or prodromal symptoms are present, according to the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists 1, 3
• Patients should be counseled to inform sex partners about having genital herpes, as recommended by the Centers for Disease Control and Prevention 1
• Patients should be counseled to use condoms during all sexual exposures with new or uninfected partners, according to the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists 1, 3
• Patients should be counseled about the risk of neonatal infection, especially for childbearing-aged women, as recommended by the Centers for Disease Control and Prevention 1
• Patients should be counseled that antiviral medications control symptoms but do not eradicate the virus or prevent all recurrences, according to the American College of Obstetricians and Gynecologists 3
• Asymptomatic viral shedding occurs more frequently in patients with HSV-2 infection than HSV-1 infection and in patients who have had genital herpes for less than 12 months, as stated by the Centers for Disease Control and Prevention 1

Special Considerations

• HSV-1 causes 5-30% of first-episode cases of genital herpes, with clinical recurrences being much less frequent than with HSV-2, according to the Centers for Disease Control and Prevention 1
• Identification of the infecting strain (HSV-1 vs HSV-2) has prognostic importance and may be useful for counseling, as recommended by the Centers for Disease Control and Prevention 1
• Antiviral resistance is rare in immunocompetent patients but more common in immunocompromised individuals, according to the American College of Obstetricians and Gynecologists 5
• For pregnant women with genital herpes, healthcare providers should be informed about the HSV infection, as recommended by the Centers for Disease Control and Prevention 1

Severe Genital Herpes Treatment

Special Considerations

• For severe disease or complications requiring hospitalization, the Centers for Disease Control and Prevention recommends acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 6
• Pregnant women with genital herpes should inform their healthcare providers about the HSV infection, and the safety of systemic acyclovir therapy during pregnancy should be discussed with patients, as recommended by the Centers for Disease Control and Prevention 6

Treatment of Genital Herpes in Females with Drainage from Lesions

Special Populations Requiring Modified Dosing

• For immunocompromised patients, higher doses of acyclovir, such as 400 mg orally three to five times daily until clinical resolution, are required, as recommended by the CDC 7
• If lesions persist despite acyclovir treatment in immunocompromised patients, suspect viral resistance and consider foscarnet 40 mg/kg IV every 8 hours, according to the MMWR Recommendations and Reports 7
• For HIV-infected patients with recurrent genital herpes, famciclovir 500 mg twice daily for 7 days is recommended, reflecting increased viral replication in this population, as stated in the MMWR Recommendations and Reports 7
• The first clinical episode during pregnancy may be treated with oral acyclovir, though safety data remain limited, as noted in the MMWR Recommendations and Reports 7
• Women receiving acyclovir or valacyclovir during pregnancy should be reported to the manufacturer's pregnancy registry, as recommended by the MMWR Recommendations and Reports 7

CDC Guidelines for the Management of Genital Herpes

Episodic Treatment of Recurrent Outbreaks

• Initiate oral antiviral therapy at the first sign of prodrome or within 1 day of lesion appearance to achieve maximal benefit. [CDC] 8
• Recommended 5‑day regimens (all supported by CDC data):
  
  • Valacyclovir 500 mg orally twice daily [9][8]
  • Acyclovir 800 mg orally twice daily [9][8]
  • Acyclovir 400 mg orally three times daily [9][8]
  • Famciclovir 125 mg orally twice daily [9][8]

Suppressive (Chronic) Therapy

• Offer daily suppressive therapy to individuals experiencing ≥ 6 recurrences per year, which reduces recurrence frequency by ≥ 75 %. [CDC] [9][8]
• Suppressive dosing options (CDC‑referenced):
  
  • Valacyclovir 500 mg orally once daily for patients with < 10 recurrences per year 9
  • Acyclovir 400 mg orally twice daily (safety documented up to 6 years) 9
  • Famciclovir 250 mg orally twice daily (safety documented up to 1 year) 9
• After 1 year of continuous suppressive therapy, discontinue temporarily to reassess recurrence frequency, as natural decline often occurs. [CDC] [9][8]

Hospitalized Severe HSV Infection

• For disseminated disease, pneumonitis, hepatitis, meningitis, or encephalitis, administer acyclovir 5–10 mg/kg IV every 8 hours for 5–7 days or until clinical resolution. [CDC] [9][8]

Management During Pregnancy

• Antiviral prophylaxis from 36 weeks gestation until delivery is recommended for women with either a first or recurrent episode to lower term‑time recurrences and cesarean‑delivery rates. [CDC] 10
• Cesarean delivery should be performed when any of the following are present at labor onset:
  
  • Suspected or confirmed first‑episode genital herpes 10
  • First episode occurring < 6 weeks before delivery 10
  • Prodrome or visible lesions at labor onset 10

Renal Function Considerations

• Assess renal function before starting and during antiviral therapy; adjust dosing frequency or total daily dose according to creatinine clearance to avoid toxicity. [CDC] 10

HIV‑Infected Patients

• For suppressive therapy, valacyclovir 500 mg orally twice daily (not once daily) is required to achieve adequate viral control. [CDC] 10
• Daily suppressive antiviral therapy reduces HIV RNA concentrations in plasma and genital secretions, although its impact on HIV transmission remains uncertain. [CDC] 10

Antiviral Resistance Management

• Suspect acyclovir resistance if lesions fail to improve within 7–10 days of appropriate therapy. [CDC] 10
• Confirm resistance with viral culture and susceptibility testing. [CDC] 10
• IV foscarnet 40 mg/kg every 8 hours is the treatment of choice for confirmed resistant HSV. [CDC] 10
• Topical cidofovir, trifluridine, or imiquimod may be used for external lesions, requiring prolonged application (≈ 21–28 days). [CDC] 10
• Resistance is uncommon in immunocompetent hosts but more frequent in immunocompromised patients, especially those with HIV on long‑term suppressive therapy. [CDC] 10

Patient Counseling Highlights

• Inform patients that asymptomatic viral shedding can occur even while on suppressive therapy, posing a transmission risk. [CDC] 9
• Emphasize that neonatal transmission risk is 25–44 % with a primary episode at delivery versus ≈ 1 % with recurrent infection. [CDC] 9
• Explain that HSV‑2 leads to more frequent asymptomatic shedding than HSV‑1, particularly during the first 12 months after infection. [CDC] 9

Clinical Pitfalls to Avoid

• Do not use valacyclovir 500 mg once daily in patients with ≥ 10 recurrences per year; it is less effective than higher‑dose regimens. [CDC] 9
• Do not delay initiation of episodic therapy; starting treatment during prodrome or within 1 day of lesion onset maximizes efficacy. [CDC] 8

CDC Recommendations for Initial Genital Herpes Management

First‑Line Oral Antiviral Regimens

• The CDC lists acyclovir 400 mg orally three times daily for 7–10 days as an accepted first‑line option for initial genital herpes in healthy adults. 11
• The CDC also recommends acyclovir 200 mg orally five times daily for 7–10 days as an alternative dosing schedule for the same indication. 11

Oral Therapy vs. Topical Therapy

• The CDC advises that topical acyclovir is substantially less effective than systemic oral antivirals and does not improve systemic symptoms, viremia, or viral shedding from sites such as the cervix, urethra, or pharynx; therefore it should not be used as monotherapy. 11

Management of Severe or Disseminated Disease

• For patients with disseminated HSV infection, encephalitis, pneumonitis, hepatitis, or inability to tolerate oral medication, the CDC recommends intravenous acyclovir 5–10 mg/kg every 8 hours for 5–7 days (or until clinical resolution). 11
• Indications for IV acyclovir according to the CDC include:

Special Consideration: Herpes Proctitis

• For a first‑episode herpes proctitis, the CDC recommends acyclovir 400 mg orally five times daily for 10 days, reflecting the need for higher dosing at the rectal site. 11

Core Patient Counseling Points (CDC)

• Genital herpes is a chronic, incurable infection with the potential for lifelong recurrences. 11
• Asymptomatic viral shedding can occur even without visible lesions, allowing transmission to partners. 11
• Patients should abstain from all sexual activity during active lesions or prodromal symptoms. 11
• Condom use is advised for all sexual encounters with new or uninfected partners, although condoms do not completely eliminate transmission risk. 11

Prescription Practices for Recurrences (CDC)

• The CDC advises that patients receive a prescription for episodic therapy to be started at the first sign of recurrence (prodrome or within 24 hours of lesion onset), emphasizing early treatment when viral replication peaks. 11

All bullet points are derived from CDC (MMWR Recommendations and Reports, 1993) and are supported by citation 11.

Antiviral Regimens for Initial Genital Herpes and Proctitis (CDC‑endorsed)

First‑Episode Treatment Options

• The CDC lists acyclovir 200 mg taken orally five times daily for 7–10 days as an acceptable first‑line oral regimen for an initial genital herpes outbreak (provides comparable efficacy to other recommended regimens) 12.

Duration for Severe Ulcerative Disease

• When genital ulcer lesions are large, treatment should be extended to at least 2 weeks to achieve complete clinical healing, because lesions may not resolve within the standard 7–10‑day course 12.

Herpes Proctitis Specific Regimen

• For a first‑episode episode of herpes proctitis, the CDC recommends acyclovir 400 mg taken orally five times daily for 10 days (higher dosing and longer duration than the standard genital herpes regimen) 12.

Genital Herpes Antiviral Management Guidelines

Acute and Hospitalized Therapy

• Oral antiviral therapy is recommended for all patients with symptomatic genital herpes, and daily suppressive therapy should be offered to those experiencing ≥ 6 recurrences per year because it reduces recurrence frequency by ≥ 75 %【13】【14】.
• For severe disease requiring hospitalization (e.g., disseminated infection, encephalitis, pneumonitis, hepatitis, or inability to tolerate oral medication), administer acyclovir 5–10 mg/kg intravenously every 8 hours for 5–7 days or until clinical resolution【15】.

Episodic (Recurrent) Therapy

• Initiate treatment at the first prodromal sign or within 24 hours of lesion onset for maximal benefit; a 5‑day regimen of valacyclovir 500 mg orally twice daily is recommended【13】.

Suppressive Therapy for Frequent Recurrences

• Daily suppressive therapy is advised for patients with ≥ 6 recurrences per year, decreasing recurrence frequency by ≥ 75 % and lowering asymptomatic viral shedding【13】【14】【15】.
• Acyclovir 400 mg orally twice daily is an evidence‑supported suppressive option with safety documented for up to six years【15】.
• After one year of continuous suppressive therapy, a temporary discontinuation is recommended to reassess recurrence frequency, as a natural decline often occurs over time【15】.

Sexual Transmission Prevention

• Patients must abstain from all sexual activity while lesions or prodromal symptoms are present【15】.
• All sexual partners should be informed of the genital herpes diagnosis【15】.
• Condom use is advised for all sexual encounters with new or uninfected partners, although condoms do not completely eliminate transmission risk【15】.
• Suppressive therapy reduces transmission to uninfected partners in HIV‑negative heterosexual couples but does not eliminate risk【13】【14】.
• Suppressive therapy does not effectively decrease transmission risk among persons co‑infected with HIV and HSV‑2【13】【14】.

Special Considerations for Immunocompromised Patients

• Higher oral acyclovir dosing (400 mg three to five times daily) is recommended for immunocompromised individuals until clinical resolution【15】.

Clinical Guidance for HSV‑2 Management (Cited Evidence)

Suppressive Therapy in HIV‑Coinfected Individuals

• Suppressive antiviral therapy does not significantly reduce genital HSV‑2 transmission risk in persons co‑infected with HIV, indicating that additional preventive measures remain necessary. 16

Antiviral‑Resistant HSV‑2 Infections

• In cases where HSV lesions fail to improve within 7–10 days of appropriate therapy, suspect aciclovir resistance; confirm with viral culture and susceptibility testing. 16
• For confirmed aciclovir‑resistant HSV, the preferred treatment is intravenous foscarnet 40 mg/kg every 8 hours. 16
• Topical agents such as cidofovir, trifluridine, or imiquimod may be employed for external resistant lesions, requiring prolonged application (approximately 3–4 weeks). 16
• Case reports suggest that brincidofovir, imiquimod, and topical cidofovir can be effective adjuncts for aciclovir‑resistant HSV infections. 16
• Helicase‑primase inhibitors (e.g., pritelivir) are under investigation in early‑phase clinical trials for resistant HSV‑2 in immunocompromised patients, though they are not yet FDA‑approved. 16

HSV‑2 Meningitis Management

• For a first episode of HSV‑2 meningitis, initiate intravenous aciclovir 10 mg/kg every 8 hours until fever and headache resolve, then transition to oral valaciclovir 1 g three times daily to complete a 14‑day course. 16
• In recurrent HSV‑2 meningitis, an entirely oral antiviral regimen may be used for the full treatment duration. 16
• Obtain cerebrospinal fluid HSV PCR in all suspected meningitis cases to confirm diagnosis. 16

Intravenous Acyclovir and Transition to Valacyclovir for Herpes CNS Infections

Indications for Intravenous Acyclovir

• Intravenous acyclovir 5–10 mg/kg every 8 hours is required for central nervous system complications of herpes infection (encephalitis, meningitis, HSV‑2 meningitis). This recommendation is based on the Clinical Infectious Diseases guideline (2022) and reflects expert consensus for severe disease management. 17

CDC Guidance for First‑Episode HSV‑2 Meningitis

• For a first episode of HSV‑2 meningitis, the CDC advises initiating acyclovir 10 mg/kg IV every 8 hours until fever and headache resolve, then switching to oral valacyclovir 1 g three times daily to complete a 14‑day course. This protocol combines IV therapy for acute control with oral therapy for completion, as outlined in the Clinical Infectious Diseases publication (2022). 17

CDC Guidelines for HSV‑2 Management

Initial Clinical Episode (First Infection)

• Treat for 7–10 days with one of the CDC‑recommended oral regimens – valacyclovir 1 g twice daily, acyclovir 400 mg three times daily, or famciclovir 250 mg three times daily – to achieve optimal lesion healing. 18
• Hospitalized patients with severe disease (e.g., disseminated infection, encephalitis, pneumonitis, hepatitis, or inability to take oral medication) should receive intravenous acyclovir 5–10 mg/kg every 8 hours for 5–7 days or until clinical resolution. 18

Episodic Therapy for Recurrent Outbreaks

• Start antiviral therapy at the prodrome or within 24 hours of lesion appearance, when viral replication peaks, to maximize clinical benefit. 18
• Standard 5‑day oral regimens (all CDC‑endorsed):
  
  • Valacyclovir 500 mg twice daily (preferred for convenience)
  • Acyclovir 800 mg twice daily
  • Acyclovir 400 mg three times daily
  • Famciclovir 125 mg twice daily
• Provide patients with a prescription or medication supply for self‑initiation at the first prodromal symptom; delaying treatment beyond 24 hours markedly reduces efficacy. 18

Daily Suppressive Therapy

• Offer suppressive therapy to individuals experiencing ≥ 6 recurrences per year, which reduces recurrence frequency by ≥ 75 %. 18
• Consider suppressive therapy for persons in serodiscordant relationships to lower transmission risk, even when recurrences are infrequent. 18
• Safety data: acyclovir 400 mg twice daily has documented safety for up to 6 years; famciclovir 250 mg twice daily is safe for up to 1 year. 18
• After one year of continuous suppressive therapy, discontinue temporarily to reassess recurrence frequency, as natural history often shows a decline over time. 18

Transmission‑Prevention Counseling

• Abstain from all sexual activity when lesions or prodromal symptoms are present to prevent viral shedding. 18
• Inform all sexual partners of the HSV‑2 diagnosis to enable shared decision‑making and risk‑reduction strategies. 18
• Use condoms for every sexual encounter with new or uninfected partners; condoms reduce but do not eliminate transmission. 18
• Recognize that asymptomatic viral shedding can occur even on suppressive therapy, maintaining a residual transmission risk. 18
• Antiviral medications control symptoms but do not eradicate HSV‑2 or prevent all recurrences. 18
• Suppressive therapy reduces transmission to uninfected partners in HIV‑negative heterosexual couples by lowering viral shedding, though risk is not eliminated. 18

Critical Pitfalls to Avoid

• Do NOT use topical acyclovir; it is substantially less effective than oral therapy and does not improve systemic symptoms or reduce viral shedding from genital or oropharyngeal sites. 18
• Do NOT delay episodic therapy beyond 24 hours after lesion onset; efficacy declines sharply after the initial viral replication peak. 18